GUANGDONG JIAYING PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.47 CNY | -4.43% |
|
-2.85% | -11.13% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,583 | 2,746 | 2,274 | 3,999 | 3,309 | 3,695 |
| Enterprise Value (EV) 1 | 2,487 | 2,720 | 2,152 | 3,787 | 3,073 | 3,361 |
| P/E ratio | 72.1 x | -22.5 x | 115 x | 2,717 x | 75.3 x | 108 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 4.81 x | 5.49 x | 4.17 x | 6.96 x | 5.02 x | 6.93 x |
| EV / Revenue | 4.63 x | 5.43 x | 3.95 x | 6.59 x | 4.66 x | 6.3 x |
| EV / EBITDA | 36.8 x | 79.2 x | 37.1 x | 65.7 x | 40.4 x | 54.6 x |
| EV / FCF | 59.2 x | 113 x | 58.5 x | 51.3 x | 534 x | 39.9 x |
| FCF Yield | 1.69% | 0.89% | 1.71% | 1.95% | 0.19% | 2.5% |
| Price to Book | 3.29 x | 4.14 x | 3.33 x | 5.84 x | 4.54 x | 4.86 x |
| Nbr of stocks (in thousands) | 507,510 | 507,510 | 507,510 | 507,510 | 507,510 | 507,510 |
| Reference price 2 | 5.090 | 5.410 | 4.480 | 7.880 | 6.520 | 7.280 |
| Announcement Date | 4/24/19 | 4/24/20 | 4/19/21 | 3/11/22 | 4/28/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 537 | 500.5 | 544.7 | 574.7 | 659.2 | 533.2 |
| EBITDA 1 | 67.61 | 34.34 | 57.95 | 57.62 | 76.04 | 61.52 |
| EBIT 1 | 40.56 | 7.181 | 29.8 | 29.29 | 50.22 | 37.31 |
| Operating Margin | 7.55% | 1.43% | 5.47% | 5.1% | 7.62% | 7% |
| Earnings before Tax (EBT) 1 | 42.33 | -114.2 | 23.02 | 5.823 | 51.1 | 39.37 |
| Net income 1 | 35.88 | -122.2 | 19.84 | 1.477 | 43.93 | 34.32 |
| Net margin | 6.68% | -24.41% | 3.64% | 0.26% | 6.66% | 6.44% |
| EPS 2 | 0.0706 | -0.2408 | 0.0391 | 0.002900 | 0.0866 | 0.0676 |
| Free Cash Flow 1 | 42.01 | 24.09 | 36.79 | 73.89 | 5.757 | 84.15 |
| FCF margin | 7.82% | 4.81% | 6.75% | 12.86% | 0.87% | 15.78% |
| FCF Conversion (EBITDA) | 62.13% | 70.16% | 63.48% | 128.24% | 7.57% | 136.78% |
| FCF Conversion (Net income) | 117.09% | - | 185.43% | 5,001.92% | 13.1% | 245.2% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/24/19 | 4/24/20 | 4/19/21 | 3/11/22 | 4/28/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 95.9 | 25.5 | 122 | 212 | 236 | 334 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 42 | 24.1 | 36.8 | 73.9 | 5.76 | 84.2 |
| ROE (net income / shareholders' equity) | 4.67% | -16.9% | 2.95% | 0.22% | 6.22% | 4.6% |
| ROA (Net income/ Total Assets) | 2.87% | 0.51% | 2.24% | 2.27% | 3.8% | 2.75% |
| Assets 1 | 1,250 | -23,762 | 886.6 | 65.19 | 1,158 | 1,247 |
| Book Value Per Share 2 | 1.550 | 1.310 | 1.350 | 1.350 | 1.440 | 1.500 |
| Cash Flow per Share 2 | 0.2300 | 0.2400 | 0.2800 | 0.4800 | 0.3700 | 0.2600 |
| Capex 1 | 8.95 | 18.8 | 11.7 | 2.34 | 2.74 | 5.06 |
| Capex / Sales | 1.67% | 3.76% | 2.14% | 0.41% | 0.42% | 0.95% |
| Announcement Date | 4/24/19 | 4/24/20 | 4/19/21 | 3/11/22 | 4/28/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.13% | 453M | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- 002198 Stock
- Financials Guangdong Jiaying Pharmaceutical Co., Ltd
